- Moody's•16 hours agoMallinckrodt plc -- Moody's: FDA Proposal to withdraw generic Concerta from the market would be negative for Lannett and Mallinckrodt
New York, October 21, 2016-- Moody's Investors Service commented that the Food and Drug Administration's proposal to withdraw approval of the Abbreviated New Drug Applications for methylphenidate HCl ER ...
- American City Business Journals•3 days ago
The Food and Drug Administration has notified Lannett Co. Inc. that the agency intends to withdraw its approval of the company’s methylphenidate hydrochloride extended-release tablets used to treat attention deficit hyperactivity disorder. The product in question is a generic version of Concerta, an ADHD drug marketed by Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals. The FDA’s decision to withdraw approval of two company’s products came after patients reported that the therapeutics benefits of extended-release generic tablets of the drug — one made by UCB/Kremers Urban Pharmaceuticals and one made by Mallinckrodt Pharmaceuticals — would wear off faster than those provided by the brand-name version.
- PR Newswire•3 days ago
PHILADELPHIA, Oct. 19, 2016 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) received a notice from the U.S. Food and Drug Administration (FDA) that it will seek to withdraw approval of the Company's ...
Lannett Company, Inc. (LCI)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||21.00 x 100|
|Ask||21.65 x 500|
|Day's Range||21.30 - 22.30|
|52wk Range||16.91 - 49.44|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.83|
|Avg Vol (3m)||1,025,258|
|Dividend & Yield||N/A (N/A)|